长效抗逆转录病毒药物市场按产品类型、作用机制、治疗领域、给药频率、治疗方法、患者类型和分销管道划分－全球预测，2026-2032年

2025 年长效抗 HIV 药物市值为 3.7686 亿美元，预计到 2026 年将成长至 4.451 亿美元，年复合成长率为 20.43%，到 2032 年将达到 13.8464 亿美元。

关键市场统计数据
基准年 2025	3.7686亿美元
预计年份：2026年	4.451亿美元
预测年份 2032	13.8464亿美元
复合年增长率 (%)	20.43%

本文简要概述了临床、监管和医疗保健服务方面的变化，这些变化将重新定义长效抗逆转录病毒疗法的依从性和治疗模式。

长效抗逆转录病毒药物的出现，标誌着临床医生、支付方和患者在爱滋病预防和慢性病管理方面取得了突破性进展。从缓释注射剂到皮下植入，这些治疗方法旨在解决依从性问题，减少给药频率，并提高不同患者群体中病毒的持续抑制率。临床医师不仅关注这些治疗方案的疗效，也日益重视它们如何重塑治疗路径、推广计画以及病患参与长期治疗的情况。

製剂技术、医疗设备和系统的最新创新如何从根本上改变了长效爱滋病治疗的治疗路径

近年来，抗爱滋病毒疗法领域经历了数次变革性变化，这主要得益于製剂科学和器械工程的进步，以及对以患者为中心的治疗效果的日益重视。长效候选药物目前采用可生物降解和不可生物降解的植入平台，以及肌肉注射和皮下注射製剂，从而实现了以往无法达到的多种给药间隔。这些技术进步正推动给药间隔从每月一次延长至每两个月一次甚至每三个月一次，进而改变治疗方法的设计和实施方式。

评估2025年关税调整如何重塑长效HIV药物生态系统的采购、製造地选择和商业合约策略。

2025年的政策环境引入了一系列关税调整，对整个医药供应链和商业策略产生了显着的下游影响。关税变化影响了进口原材料、专用给药装置以及长效製剂中使用的某些中间体的成本基础。随着上游采购成本的波动，製造商重新评估了筹资策略和近岸外包方案，以降低贸易政策波动带来的风险，同时维持可预测的生产计画。

全面的細項分析揭示了产品类型、作用机制、治疗标靶、给药间隔、通路、患者群体和治疗方法的选择将如何影响产品开发和商业化。

长效抗HIV产品的細項分析揭示了不同的临床和商业性路径，每条路径都需要专门的研发和上市策略。植入和注射剂产品类型的区别导致了不同的考虑因素。对于植入，可生物降解基质与不可生物降解基质的选择会影响移除程序和装置监测；而对于注射剂而言，需要针对肌肉或皮下给药进行製剂优化，这会影响基于场所或基于社区的给药模式。按作用机制进行细分錶明，整合酶抑制剂、蛋白酶抑制剂和逆转录酶抑制剂各自具有独特的抗药性特征、相互作用风险和製剂限制，这些都会影响联合治疗治疗策略与单药治疗策略的发展。

区域性趋势和实施考量将决定长效抗病毒干预措施在不同医疗保健系统中的监管、采用和推广方式。

长效抗逆转录病毒疗法的采纳和部署在各地区的趋势反映了不同的卫生系统结构、监管路径和流行病学重点。在美洲，对诊所基础设施的投资以及支付方对新型给药方式的支持意愿正在加速都市区的推广应用，同时公共卫生计画正致力于将长效疗法纳入现有的预防和治疗策略。在欧洲、中东和非洲地区，获取途径则呈现分化趋势。儘管存在监管协调努力和国家筹资策略，但医疗服务能力差异巨大，这不仅为精准部署提供了机会，也为公平分配带来了挑战。

开发商、设备合作伙伴和製造专家之间的策略竞争格局和合作框架将决定产品部署动能和商业化准备。

该领域的竞争与合作格局正由众多参与者共同塑造，其中包括成熟的製药公司、专业的生物技术创新者以及专注于药物递送平台的医疗器材製造商。主要企业将深厚的抗病毒药理学知识与缓释技术能力相结合，药物研发企业与医疗器材工程师之间建立策略联盟以加速联合开发已成为常态。对製剂科学的投入，尤其是在确保可预测的释放曲线和最大限度减少注射部位及植入相关併发症，仍然是竞争对手之间关键的差异化因素。

为确保供应链的韧性、与支付方合作以及部署以患者为中心的长效治疗方法，开发人员和商业领导者应制定可操作的跨职能优先事项。

产业领导者应推动一系列切实可行的倡议，将科学进步转化为持续的临床影响和商业性成功。首先，应优先制定整合开发计划，从早期阶段就将製剂技术、器械设计和监管策略协调一致，以最大限度地减少后期变更并简化核准流程。其次，应投资于灵活的生产製造和双源筹资策略，以增强因应政策引发的供应中断的能力，并支持区域上市计画。第三，应设计差异化的患者支持模式，使其能够适应不同的给药频率和给药环境，确保成人和儿童患者群体都能获得量身定制的教育和监测。

严谨的质性、以文献为基础的调查方法，整合了相关人员访谈、临床文献和政策分析，以得出可操作的策略见解和限制。

本分析的研究结合了最新临床文献、监管指导文件和公共声明的系统性回顾，以及与研发、生产和支付方等各领域专家的专案咨询。主要资讯来源包括对具有长效製剂给药经验的临床医生、专注于医疗设备-药物组合的监管事务专家以及负责区域製造地的供应链高管的访谈。这些质性研究辅以已发表的安全性和药物动力学研究、监管文件和产品生命週期资讯披露的次要分析，以确保临床证据与策略意义相符。

本报告将临床前景与系统层面的必要性相结合，阐述了产业界和医疗卫生系统之间的合作努力将如何决定持续治疗方法在现实世界中的成功。

长效抗爱滋病毒疗法正在重塑临床策略，其提供的全新治疗方法能够提高患者依从性，减少就诊次数，并在整个预防和治疗人群中持续发挥疗效。製剂创新、医疗设备的不断发展以及医保报销模式的转变，共同创造了机会，同时也带来了挑战。製造商必须平衡药物的药理性能和给药的便捷性，而医疗系统则必须调整基础设施和支付方结构，以支持更广泛的应用。无论在哪个地区，制定符合当地实际情况的推广策略对于将临床疗效转化为真正的公共卫生效益至关重要。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的长效抗HIV药物市场

• 植入
  • 可生物降解
  • 不可生物降解
• 注射
  • 肌肉内注射
  • 皮下注射

9. 依作用机转分類的长效抗HIV药物市场

• 整合酶抑制剂
• 蛋白酶抑制剂
• 逆转录酶抑制剂

第十章：依治疗领域分類的长效抗HIV药物市场

• 预防
• 治疗

11. 依给药频率分類的长效抗HIV药物市场

• 每隔一个月
• 每月一次
• 季刊

12. 依治疗方法的长效抗HIV药物市场

• 联合治疗
  • 三联联合治疗
  • 双药联合治疗
• 单药治疗

第十三章：依病患类型分類的长效抗HIV药物市场

• 成人版
• 儿童

第十四章 长效抗爱滋病药物市场（依通路划分）

• 离线
• 在线的

第十五章 各地区长效抗爱滋病毒药物市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章：按组别分類的长效抗HIV药物市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 各国长效抗爱滋病毒药物市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

18. 美国长效抗爱滋病毒药物市场

第十九章 中国的长效抗爱滋病药物市场

第20章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Accord Healthcare Inc.
• Amneal Pharmaceuticals, Inc.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Genentech, Inc.
• Gilead Sciences, Inc.
• Hetero Labs Limited
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Mylan NV
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Theratechnologies Inc.
• Viatris Inc.
• ViiV Healthcare Limited

The Long-acting Anti-HIV Drugs Market was valued at USD 376.86 million in 2025 and is projected to grow to USD 445.10 million in 2026, with a CAGR of 20.43%, reaching USD 1,384.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 376.86 million
Estimated Year [2026]	USD 445.10 million
Forecast Year [2032]	USD 1,384.64 million
CAGR (%)	20.43%

A concise orientation to the clinical, regulatory, and care delivery shifts sparked by long-acting anti-HIV therapies that redefine adherence and treatment paradigms

The advent of long-acting anti-HIV therapeutics represents a pivotal evolution in how clinicians, payers, and patients approach both prevention and chronic management of HIV. These modalities-ranging from extended-release injectables to subdermal implants-are designed to address adherence challenges, reduce dosing frequency, and improve sustained viral suppression in diverse patient populations. Clinicians are increasingly evaluating these options not only on efficacy but on how they reshape care pathways, outreach programs, and long-term therapeutic engagement.

As development programs move forward, stakeholders across the ecosystem are adapting clinical protocols, supply chains, and patient education strategies to accommodate devices and formulations that require distinct administration settings and monitoring. Regulatory authorities are clarifying requirements for pharmacokinetic bridging and device-related safety, prompting sponsors to embed robust real-world evidence collection early in development. Payors and health systems are beginning to model the operational implications of these therapies, considering administration costs, training burdens, and potential reductions in downstream morbidity.

Taken together, these dynamics are shifting the conversation from incremental product improvement toward system-level transformation, where long-acting options are considered instruments of care redesign. The following sections explore the technological, commercial, and policy inflection points that are driving adoption, segmentation dynamics, regional variation, and the strategic actions companies should prioritize.

How recent formulation, device and systemic innovations have catalyzed a fundamental reorientation of treatment pathways for long-acting anti-HIV therapies

In recent years the landscape for anti-HIV treatment has experienced several transformative shifts driven by advances in formulation science, device engineering, and an intensified focus on patient-centric outcomes. Long-acting drug candidates now leverage biodegradable and non-biodegradable implant platforms as well as intramuscular and subcutaneous injectable formulations, enabling a range of administration cadences that were previously unattainable. These technical capabilities have opened routes for extending intervals between doses from monthly to bi-monthly and even quarterly schedules, which in turn are changing how therapeutic regimens are conceived and operationalized.

Concurrently, mechanistic innovation across integrase inhibitors, protease inhibitors, and reverse transcriptase inhibitors has deepened the pharmacologic toolkit available to developers. Combination regimens that include two- or three-drug approaches are being reconsidered through the lens of long-acting delivery, with attention to drug-drug compatibility, release kinetics, and sustained therapeutic windows. The shift toward fixed long-acting regimens has prompted clinical investigators to explore new endpoints and adherence metrics while encouraging manufacturers to pursue device-drug co-development strategies.

Policy and payer environments are also evolving, with reimbursement discussions now encompassing administration settings such as hospital pharmacies, retail outlets, and emerging online pharmacy models for coordinating home administration. Together, these technological and systemic shifts are not just introducing new products but catalyzing a redefinition of patient journeys, clinical workflows, and commercial models across the broader HIV care continuum.

An assessment of how 2025 tariff adjustments reshaped sourcing, manufacturing footprint decisions, and commercial contracting strategies across the long-acting anti-HIV ecosystem

The policy landscape entering 2025 introduced a set of tariff adjustments that have created palpable downstream effects across pharmaceutical supply chains and commercial strategies. Tariff changes influenced the cost base for imported raw materials, specialized delivery devices, and certain intermediate components used in long-acting formulations. As upstream procurement costs shifted, manufacturers reassessed sourcing strategies and nearshoring options to mitigate exposure to trade policy volatility and to maintain predictable production schedules.

These tariff-driven cost pressures accelerated conversations about vertical integration for critical components, fostering partnerships between drug developers and component suppliers that prioritize supply continuity and quality assurance. In parallel, firms revisited distribution footprints, weighing the relative efficiency of centralized manufacturing against regional fill-and-finish operations to reduce cross-border movement of finished products and thereby minimize tariff impacts.

Health system purchasers and formularies adapted contracting approaches by emphasizing value-based arrangements and multi-year supply commitments that provide predictability for both buyers and manufacturers. The cumulative effect has been a recalibration of procurement, manufacturing location decisions, and strategic sourcing models, highlighting the need for agile commercial planning that internalizes trade policy as a persistent variable rather than a transient disruption.

Comprehensive segmentation intelligence revealing how product type, mechanism, therapy focus, dosing cadence, channel, patient cohort, and regimen choices shape development and commercialization

Segmentation insights for long-acting anti-HIV products reveal differentiated clinical and commercial pathways that require tailored development and go-to-market approaches. Product type distinctions between implants and injectables drive divergent considerations: implants present choices between biodegradable and non-biodegradable matrices with implications for removal procedures and device surveillance, while injectables require formulation optimization for intramuscular or subcutaneous delivery and influence clinic-based versus community-based administration models. Mode of action segmentation illustrates how integrase inhibitors, protease inhibitors, and reverse transcriptase inhibitors each bring unique resistance profiles, interaction risks, and formulation constraints that shape combination versus monotherapy strategies.

Therapy area classification into prevention and treatment delineates distinct stakeholder value propositions and trial designs; prevention products often emphasize tolerability and long-term safety in otherwise healthy populations, whereas treatment-focused options stress virologic suppression durability and co-morbidity management. Variability in dosing frequency-bi-monthly, monthly, and quarterly-creates strategic trade-offs between patient convenience, adherence monitoring, and clinic visit cadence, necessitating different support programs and patient engagement models. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy influences access pathways and reimbursement mechanisms, while patient type distinctions between adult and pediatric populations demand separate pediatric formulation development, dosing studies, and caregiver-focused adherence supports. Lastly, treatment regimen segmentation into combination and monotherapy frameworks, with combination options further distinguished by two-drug or three-drug regimens, drives complexity in pharmacokinetic compatibility studies and regulatory strategies, and informs commercial differentiation and positioning.

Region-specific dynamics and implementation considerations that determine how long-acting anti-HIV interventions are regulated, adopted, and scaled across diverse healthcare systems

Regional dynamics in the adoption and deployment of long-acting anti-HIV therapies reflect heterogeneous health system structures, regulatory pathways, and epidemiologic priorities. In the Americas, investment in clinic infrastructure and payer willingness to support novel administration modalities have enabled accelerated uptake in urban centers, while public health programs focus on integrating long-acting options into existing prevention and treatment initiatives. Europe, Middle East & Africa present a wide spectrum of pathways to access: regulatory harmonization efforts and national procurement strategies coexist with significant variability in healthcare delivery capacity, creating both opportunities for targeted rollouts and challenges around equitable distribution.

Asia-Pacific markets show a mix of vibrant local manufacturing capabilities, regulatory innovation in accelerated pathways, and evolving payer frameworks that influence how long-acting agents are reimbursed and distributed. Cross-region partnerships and technology transfer initiatives are increasingly important for expanding production capacity and ensuring supply resilience, with multilateral organizations playing a role in coordinating procurement and training programs. These geographic distinctions emphasize that commercial strategies must be regionally adapted, combining centralized evidence generation with localized implementation plans to address differences in healthcare delivery, regulatory expectations, and patient population needs.

Strategic competitive profiles and collaboration frameworks among developers, device partners, and manufacturing specialists that determine product momentum and commercialization readiness

The competitive and collaborative contours of the sector are shaped by an array of established pharmaceutical companies, specialist biotech innovators, and device manufacturers focused on delivery platforms. Leading developers are combining depth in antiviral pharmacology with capabilities in sustained-release technologies, and strategic alliances between drug sponsors and device engineers are common to accelerate co-development. Investment into formulation science, particularly for ensuring predictable release profiles and minimizing injection-site or implant-related complications, remains a primary differentiator among competitors.

Partnership models are also evolving; companies increasingly pursue co-development, licensing, and supply agreements to accelerate time-to-market and to de-risk manufacturing scale-up. Clinical operations partners with experience in long-duration studies and community-based delivery channels are highly valued, as are contract manufacturers capable of aseptic injectable fill-finish and implant fabrication at scale. Additionally, several firms are investing in patient support platforms, digital adherence tools, and training programs for administration to reduce barriers to uptake. Overall, firms that integrate technical excellence with pragmatic commercialization capabilities-such as robust distribution networks and payer engagement strategies-are best positioned to translate clinical advances into sustained clinical and commercial traction.

Actionable, cross-functional priorities for developers and commercial leaders to ensure resilient supply chains, payer alignment, and patient-centric adoption of long-acting therapies

Industry leaders should advance a set of pragmatic, actionable initiatives to convert scientific progress into durable clinical impact and commercial success. First, prioritize integrated development plans that align formulation, device engineering, and regulatory strategy from early stages to minimize later-stage changes and to streamline approval pathways. Second, invest in flexible manufacturing and dual-sourcing strategies to build resilience against policy-driven supply disruptions and to support regional launch plans. Third, design differentiated patient support models that adapt to dosing frequency and administration setting, ensuring both adult and pediatric cohorts receive tailored education and monitoring.

Fourth, engage payers and health systems early to articulate value propositions that reflect reduced adherence burdens, potential downstream cost offsets, and population health benefits. Fifth, pursue strategic alliances for distribution and last-mile delivery, leveraging hospital, retail, and online pharmacy networks to broaden access while maintaining cold chain and administration quality. Sixth, incorporate real-world evidence frameworks into post-approval plans to demonstrate long-term safety, adherence impact, and comparative effectiveness across prevention and treatment populations. By executing these steps in parallel, leaders can reduce time-to-impact and foster adoption pathways that align clinical benefit with sustainable commercial models.

Rigorous qualitative and document-based methodology integrating stakeholder interviews, clinical literature, and policy analysis to derive actionable strategic insights and limitations

The research underpinning this analysis combined a systematic review of contemporary clinical literature, regulatory guidance documents, and public policy statements with targeted expert consultations across development, manufacturing, and payer domains. Primary inputs included interviews with clinicians experienced in long-acting administration, regulatory affairs specialists focused on device-drug combinations, and supply chain executives overseeing regional manufacturing footprints. These qualitative engagements were complemented by secondary analysis of published safety and pharmacokinetic studies, regulatory filings, and product lifecycle disclosures to ensure alignment between clinical evidence and strategic implications.

Methodologically, triangulation was used to validate insights, reconciling divergent perspectives across stakeholders and corroborating operational implications with documented clinical outcomes. Where appropriate, scenario-based analysis was applied to evaluate the effects of tariff adjustments and distribution channel shifts on procurement and launch strategies. Limitations of the methodology are acknowledged, particularly where emerging clinical data remain immature; in such cases, recommendations emphasize adaptive planning and iterative evidence generation to inform decision-making as new data become available.

A synthesis of clinical promise and system-level imperatives that explains how coordinated industry and health system actions will determine the real-world success of long-acting therapies

Long-acting anti-HIV therapies are reshaping clinical strategy by offering new modalities to address adherence, reduce visit frequency, and sustain therapeutic effect across prevention and treatment populations. The intersection of formulation innovation, device evolution, and evolving reimbursement models has created both opportunity and complexity: manufacturers must balance pharmacologic performance with delivery practicality, while health systems must adapt infrastructure and payer constructs to support broader adoption. Across regions, tailored implementation strategies are essential to translate clinical promise into realized public health benefit.

Manufacturers and health system leaders should therefore approach the field with an integrated mindset that aligns clinical development, manufacturing resilience, market access planning, and patient support ecosystems. Where policy or tariff volatility exists, building operational flexibility is critical. Ultimately, the potential of long-acting therapies to improve adherence and outcomes will be realized through coordinated efforts across clinical, commercial, and public health stakeholders that prioritize equitable access and sustainable delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Anti-HIV Drugs Market, by Product Type

• 8.1. Implant
  • 8.1.1. Biodegradable
  • 8.1.2. Non-Biodegradable
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Subcutaneous

9. Long-acting Anti-HIV Drugs Market, by Mode Of Action

• 9.1. Integrase Inhibitor
• 9.2. Protease Inhibitor
• 9.3. Reverse Transcriptase Inhibitor

10. Long-acting Anti-HIV Drugs Market, by Therapy Area

• 10.1. Prevention
• 10.2. Treatment

11. Long-acting Anti-HIV Drugs Market, by Dosing Frequency

• 11.1. Bi-Monthly
• 11.2. Monthly
• 11.3. Quarterly

12. Long-acting Anti-HIV Drugs Market, by Treatment Regimen

• 12.1. Combination
  • 12.1.1. Three Drug Regimen
  • 12.1.2. Two Drug Regimen
• 12.2. Monotherapy

13. Long-acting Anti-HIV Drugs Market, by Patient Type

• 13.1. Adult
• 13.2. Pediatric

14. Long-acting Anti-HIV Drugs Market, by Distribution Channel

• 14.1. Offline
• 14.2. Online

15. Long-acting Anti-HIV Drugs Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Long-acting Anti-HIV Drugs Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Long-acting Anti-HIV Drugs Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. United States Long-acting Anti-HIV Drugs Market

19. China Long-acting Anti-HIV Drugs Market

20. Competitive Landscape

• 20.1. Market Concentration Analysis, 2025
  • 20.1.1. Concentration Ratio (CR)
  • 20.1.2. Herfindahl Hirschman Index (HHI)
• 20.2. Recent Developments & Impact Analysis, 2025
• 20.3. Product Portfolio Analysis, 2025
• 20.4. Benchmarking Analysis, 2025
• 20.5. Accord Healthcare Inc.
• 20.6. Amneal Pharmaceuticals, Inc.
• 20.7. Aurobindo Pharma Ltd.
• 20.8. Cipla Ltd.
• 20.9. Dr. Reddy's Laboratories Ltd.
• 20.10. Genentech, Inc.
• 20.11. Gilead Sciences, Inc.
• 20.12. Hetero Labs Limited
• 20.13. Johnson & Johnson
• 20.14. Lupin Limited
• 20.15. Merck & Co., Inc.
• 20.16. Mylan N.V.
• 20.17. Sun Pharmaceutical Industries Ltd.
• 20.18. Teva Pharmaceutical Industries Ltd.
• 20.19. Theratechnologies Inc.
• 20.20. Viatris Inc.
• 20.21. ViiV Healthcare Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 15. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 79. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 80. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 81. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 82. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 90. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 92. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 93. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 101. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 103. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 110. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 111. LATIN AMERICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 128. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 129. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 130. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 131. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 132. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 133. EUROPE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 137. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 138. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 139. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 140. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 141. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 142. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 143. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 144. MIDDLE EAST LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 147. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 148. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 149. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 150. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 151. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 152. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 153. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 154. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 155. AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 156. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 158. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 159. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 160. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 161. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 162. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 163. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 164. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 165. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 166. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 168. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 169. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 170. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 171. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 172. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 173. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 174. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 175. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 176. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 177. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 178. ASEAN LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 179. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 180. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 181. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 182. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 183. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 184. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 185. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 186. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 187. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 188. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 189. GCC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 190. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 191. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 192. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 193. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 194. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 195. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 196. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 197. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 198. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 199. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 200. EUROPEAN UNION LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 201. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 202. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 203. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 204. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 205. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 206. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 207. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 208. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 209. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 210. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 211. BRICS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 212. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 213. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 214. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 215. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 216. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 217. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 218. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 219. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 220. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 221. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 222. G7 LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 223. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 224. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 225. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 226. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 227. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 228. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 229. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 230. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 231. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 232. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 233. NATO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 234. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 235. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 236. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 237. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 238. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 239. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 240. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 241. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 242. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 243. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 244. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 245. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 246. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 247. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 248. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
• TABLE 249. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
• TABLE 250. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
• TABLE 251. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 252. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
• TABLE 253. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
• TABLE 254. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2032 (USD MILLION)
• TABLE 255. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 256. CHINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)